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Abstract 
Background: Most women with primary breast cancers that express estrogen receptor alpha (ER or ESR1) are treated 
with endocrine therapies including the anti-estrogen tamoxifen, but resistance to these anti-endocrine therapies 
often develops. This study characterizes the expression of hormone receptors, and the mRNA and DNA methylation 
levels of docking protein 7 (DOK7), and E74-like factor 5 (ELF5), in 21 novel tamoxifen-resistant cell lines and extends 
the findings to primary and recurrent human breast tumors.
Methods: Twenty-one tamoxifen-selected cell lines were developed through cloning by limiting dilution of an 
MCF-7 cell culture treated with 1 μM tamoxifen for 6 months. The parent (MCF-7) and tamoxifen-selected cell lines 
were characterized for protein expression of ER, progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) using immunohistochemistry (IHC). The mRNA levels of ER, DOK7, and ELF5 were assessed using 
quantitative RT-PCR. Promoter methylation levels of DOK7 and ELF5 were determined by pyrosequencing of bisulfite-
modified DNA. The relationship between hormone receptor status and promoter methylation of DOK7 and ELF5 was 
further examined using available methylation array data (Illumina HM450) from a set of paired primary and second 
breast tumors from 24 women.
Results: All 21 of the novel tamoxifen-selected cell lines are ER-positive, and HER2-negative, and 18 of the cell lines 
are PR-negative while the MCF-7 cells were scored as ER-positive, modestly PR-positive and HER2 negative. Expression 
of DOK7 and ELF5 is significantly up-regulated in half of the tamoxifen-selected cell lines as compared to the parental 
MCF-7. In contrast, the previously established ER-negative TMX2-28 cell line has decreased expression of both DOK7 
and ELF5 and increased DNA methylation in the transcriptional start site region of these genes. ELF5 methylation was 
lower in second versus primary tumors in women who received anti-estrogen treatment, in PR-negative versus PR-
positive tumors, and in the subset of PR-positive first tumors from the group of women who had second PR-negative 
tumors as compared to those who had second PR-positive tumors.
Conclusions: The distinct ELF5 methylation of PR-positive primary tumors from women who had a PR-negative 
recurrence indicates the possibility of stratification of women for tailored treatment in the early stages of disease.
Keywords: Breast cancer, DOK7, ELF5, Estrogen receptor, Progesterone receptor, Tamoxifen resistance
© 2016 Fitzgerald et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Approximately 80  % of primary breast cancers express 
estrogen receptor α (ER), a nuclear transcription factor 
that is the product of the ESR1 gene [1–3]. Aromatase 
inhibitors and anti-estrogens such as tamoxifen are used 
to treat these estrogen receptor positive (ER+) cancers, 
and act to reduce the growth-promoting effects of estro-
gen. However, 33  % of women treated with tamoxifen 
see a recurrence in their breast cancer within 5  years, 
and resistance to all endocrine therapies is common [4]. 
Many potential molecular changes could allow breast 
cancer cells to continue growth in the absence of estro-
gen, and the acquired drug resistance is incompletely 
understood. Mutations to the ESR1 gene [1, 5], chromatin 
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restructuring [6], and disruption of many cellular path-
ways [7, 8] have been described in endocrine resistant 
breast cancers, as reviewed [9–11]. We have previously 
shown that tamoxifen treatment alters DNA methylation 
of various genes involved in cell growth in breast cancer 
cell lines [12].
Despite their insensitivity to tamoxifen, most resist-
ant breast cancers still express ER [9]. Resistant cell lines 
developed in previous experiments were primarily ER+, 
with exceptions such as the triple negative, TMX 2-28 
[13, 14]. The characterization of our novel cell lines began 
with measuring the intracellular protein levels of three 
receptors: ER, progesterone receptor (PR), and human 
epidermal growth factor 2 (HER2). The intracellular pro-
tein levels of ER, PR, and HER2 in breast cancers often 
advise the treatment choices for the patient. Cancers with 
decreased levels of PR are more likely to become resist-
ant to endocrine therapy [15], and HER2 overexpression 
is known to promote tamoxifen resistance via cross-talk 
with ER [16].
Due to the frequency of acquired endocrine resistance 
and the lack of treatment for this type of breast cancer, 
many researchers have studied biological mechanisms 
that predict acquired endocrine resistance. One recently 
recognized marker of acquired endocrine resistance 
is E74-liked factor 5 (ELF5) [8]. ELF5 is a transcription 
factor involved in keratinocyte and mammary gland dif-
ferentiation, especially alveolar differentiation, milk 
secretion and ductal morphogenesis [17]. ELF5 is fre-
quently down-regulated in breast cancer [18]. A recent 
study identified ELF5 as playing a potential role in the 
development of tamoxifen resistance that is positively 
correlated to ER expression [8]. Progesterone has been 
shown to induce ELF5 levels, and the action of proges-
terone on ELF5 expression in alveolar development is 
thought to be via a paracrine mechanism [19]. For the 
above reasons, ELF5 expression in each of our tamoxifen-
selected novel cell lines was compared to that in MCF-7, 
as well as that in the previously established tamoxifen-
resistant cell lines: TMX2-4, TMX2-11 and TMX2-28.
Additionally, expression and methylation of docking 
protein 7 (DOK7) were measured due to the protein’s 
potential role as a tumor suppressor. A recent study of 
identical twins with differential breast cancer statuses 
identified DOK7 gene methylation as an indicator of 
breast cancer risk [20]. Increased expression of DOK7 
has been correlated with longer patient survival time, 
and decreased expression of the gene has been seen in 
patients with recurrent cancers [21]. To our knowledge, a 
role of DOK7 in tamoxifen resistance has not been previ-
ously studied.
In this study, we sought to characterize tamoxifen-
selected MCF-7 derivative cell lines based on changes in 
the expression and methylation of DOK7, ELF5, and ERα, 
and the protein levels of ERα, PR, and HER2. To extend 
these findings clinically, we examined the relationship 
between hormone receptor status, anti-estrogen treat-
ment and promoter methylation of DOK7 and ELF5 in 
a set of matched primary and recurrent breast tumors 
from 24 women.
Results and discussion
Novel tamoxifen‑selected cell lines phenotypically 
resemble the parental line
During the initial expansion of the tamoxifen-selected 
cell lines, a few of the cell lines appeared to grow either in 
unusual clumps or in suspension. However, after several 
passages in T-75 flasks all of the tamoxifen-selected lines 
displayed a phenotype similar to that of MCF-7 (Fig. 1).
Novel tamoxifen‑selected cell lines are ER‑positive and PR‑ 
and HER2‑negative
Blinded observers (pathologists RMJ and CNO) assessed 
IHC-stained slides for ER, PR and HER2. ER protein 
expression in the 21 tamoxifen-selected cell lines was 
similar to that observed in the parental MCF-7 (Figs. 2, 
3a). Nineteen of the tamoxifen-selected cell lines received 
an Allred score of 7, and one line each received an All-
red score of 5 and 6, which is only slightly higher than the 
score of 6 routinely assigned ER staining in MCF-7 [22]. 
In contrast, the protein expression for PR was substan-
tially lower in the tamoxifen-selected cell lines than in 
the parental MCF-7 (Figs. 2, 3a). For progesterone recep-
tor, six cell lines received an Allred score of 0, thirteen 
lines received a score of 2, and one line each received a 
score of 3 and 4. Allred scores of two and less are con-
sidered PR-negative. Thus, only two of the 21 cell lines 
were scored positive for PR and these positive scores are 
still considerably lower than the typical Allred score of 
6 assigned for PR staining in MCF-7 [22]. HER2 protein 
expression was similar between the parental and tamox-
ifen-selected cell lines with all lines receiving a score of 0 
or 1+ (Figs. 2, 3a).
Comparison of mRNA levels in parental, novel 
and previously established tamoxifen‑selected cell lines
Having established with IHC that the novel tamoxifen-
selected cell lines were ER-positive, PR-negative (18 
of 21), and HER2-negative, we wanted to examine the 
expression of additional genes that might play a role in 
endocrine resistance, and compare the expression in 
the novel cell lines with the expression in several previ-
ously described tamoxifen-resistant cell lines, TMX2-28, 
TMX2-11, and TMX2-4 [13, 23]. We began with a com-
parison of ESR1 mRNA levels to confirm the ER-immu-
nostaining data. As expected, based on the protein data, 
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the ESR1 mRNA levels of the novel tamoxifen-selected 
cell lines did not differ significantly from the parental 
MCF-7 (Fig. 3b). Interestingly, however, the ESR1 mRNA 
levels for the majority of the cell lines were slightly lower 
than that of MCF-7. In comparison, ESR1 expression is 
significantly higher in TMX2-11 as compared to MCF-7 
(p < 0.001) and significantly lower in TMX2-28 as com-
pared to MCF-7 (p < 0.001), confirming previous reports 
[13, 23].
We next compared the expression of DOK7 mRNA 
in MCF-7 with the expression in all of the tamoxifen-
selected lines and the mass culture TMX3A. DOK7 was 
significantly overexpressed in eleven of the 21 novel 
tamoxifen-selected cell lines (p < 0.05) and was not sig-
nificantly altered in any of the other cell lines or in the 
mass culture (Fig. 4). Interestingly, DOK7 expression was 
reduced, although not significantly, in TMX2-28 the only 
ER-negative tamoxifen-resistant cell line examined. Next, 
we compared ELF5 expression in MCF-7 with the expres-
sion in all of the tamoxifen-selected lines and the mass 
culture. ELF5 was significantly over expressed in ten of 
the 21 novel cell lines (p < 0.01) and not in the mass cul-
ture or the previously described cell lines (Fig. 5). Again, 
expression was decreased, but not significantly, in the 
ER-negative TMX2-28 cell line. There was limited over-
lap between the tamoxifen-selected cell lines with ele-
vated DOK7 mRNA levels and those with elevated ELF5 
mRNA levels; only three cell lines (clones 6, 7 and 19) 
had increased expression of both genes.
DNA Promoter methylation of DOK7 and ELF5 in cell lines
Given that the expression of DOK7 and ELF5 was signifi-
cantly increased in roughly half of the novel tamoxifen-
selected, ER–positive cell lines, and decreased (although 
not significantly) in the only ER-negative cell line, TMX2-
28, we wanted to determine the extent to which DNA 
methylation in the promoter region of DOK7 and ELF5 
controlled gene expression. If DNA promoter methyla-
tion was controlling expression we would expect to see 
a decrease in methylation associated with the up-regula-
tion observed in the novel tamoxifen-selected cell lines, 
and an increase in DNA methylation associated with the 
down-regulation observed in the TMX2-28 cell line.
We first examined DNA methylation data available 
from the Illumina human methylation 450K bead chip 
(HM450BC) for MCF-7, TMX2-11 and TMX2-28 [12]. 
The HM450BC includes nine CpGs within the tran-
scriptional start site (TSS) of DOK7, and eight CpGs 
within the TSS-region of ELF5. As shown in the heat 
maps of Fig.  6, the methylation in the TSS region of 
both DOK7 and ELF5 are substantially increased in 
TMX2-28 cells as compared to MCF-7 and TMX2-11. 
The increase in methylation observed in TMX2-28 cells 
is consistent with the lower expression of DOK7 and 
ELF5 in this cell line and suggests that promoter meth-
ylation in DOK7 and ELF5 may control gene expres-
sion. The results from TMX2-28 are in agreement with 
the inverse association between promoter methylation 
Fig. 1 Phenotypic characterization of tamoxifen-selected cell lines. 
Representative phase-contrast photomicrographs of the parental 
MCF-7 (top panel) and two clonal cell lines: Tamoxifen-selected 
clone #6 (middle panel) and tamoxifen-selected clone #15 (bottom 
panel). Images were taken at ×25 original magnification and scale 
bar = 50 μM. All clonal cell lines were phenotypically similar to the 
parental MCF-7 cell line and grew at similar rates
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and gene expression previously demonstrated for ELF5 
[24–26] and DOK7 [27]. In contrast, the increased 
expression of both ELF5 and DOK7 observed among a 
subset of the ER-positive, tamoxifen-selected, cell lines 
cannot be attributed to a decrease in promoter meth-
ylation as compared to the parental cell line, since the 
parental MCF-7 methylation is already near zero at the 
majority of tested sites.
To confirm the methylation results observed with the 
HM450BC we designed pyrosequencing assays to inter-
rogate six CpG sites within the TSS of DOK7 and three 
CpG sites within the TSS of ELF5. Figure  7a shows the 
pyrosequencing results for MCF-7, TMX2-4, TMX2-
11, TMX2-28, the mass culture TMX3A and several 
TMX3A clonal cell lines for DOK7. As expected, only the 
ER-negative TMX2-28 cell line has increased DNA meth-
ylation. Average DOK7 methylation in TMX2-28 cells 
was 35.7 %, whereas average methylation of MCF-7 was 
3.3  % and TMX3A was 4.2  %. Pyrosequencing of all 21 
novel tamoxifen-selected cell lines showed no differences 
in DNA methylation in DOK7 as compared to the parent 
MCF-7 (6 representative tamoxifen-selected cell lines are 
shown).
Likewise, increased DNA methylation of ELF5 was 
observed only for TMX2-28 (Fig.  7b). Average DNA 
methylation of ELF5 in TMX2-28 was 74.9 % compared 
to MCF-7 at 5.5 %, and TMX2-4, 2-11 and TMX3A (mass 
culture) at 4.5, 5.75, and 6  %, respectively. Additionally, 
all 21 tamoxifen-selected clonal cell lines, six of which are 
shown in Fig. 7b, had low methylation of ELF5.
Fig. 2 Hormone receptor status of cell lines. Immunohistochemistry results for estrogen receptor (ER), progesterone receptor (PR) and human epi-
dermal growth factor receptor 2 (HER2) in MCF-7, and a representative tamoxifen-selected clonal cell line (clone 3) are shown. Images were taken at 
×200 original magnification. PR staining was weaker in 85 % of the tamoxifen-selected clones compared to the parent cell line
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DNA methylation of DOK7 and ELF5 in paired primary 
and second breast tumors
We next examined DNA methylation in primary and 
second/recurrent breast tumors from three groups of 
women (Table  1) to determine the extent to which the 
tamoxifen-related changes observed in cell culture also 
occurred in the tumors of women treated with anti-
hormonal therapy. Primary and recurrent tumors were 
categorized by PR status because PR expression is an 
indication of ER activity [28]. Furthermore, in the major-
ity of novel tamoxifen-selected clones described in this 
report, decreases in PR expression were accompanied 
by increases in ELF5 and DOK7 expression. As shown 
in Table 1, all 16 women who had a PR-positive primary 
tumor received hormonal therapy, and 10 of the 16 are 
known to have received tamoxifen (primary tumors from 
groups 1 and 2: tamoxifen 10; aromatase inhibitors 2; 
type of hormonal therapy unknown 4). Additionally, 3 of 
the 8 women with PR-negative primary tumors (group 3) 
received hormonal therapy because their primary tumor 
was ER-positive.
Comparison of DOK7 promoter methylation across the 
primary and second tumors of women in the three groups 
showed no differences (Fig.  8a); median mean methyla-
tion for the 9 CpGs sites within the TSS was below 10 % 


















































ER 8 8 8 0 8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 6 7 7 7 7 
PR 4 3 3 0 2 0 4 2 2 3 2 2 0 2 0 2 2 0 2 0 0 2 2 2 2 
HER2 0 1 1 0 0 1 1 1 1 0 1 1 0 1 0 1 0 0 0 0 0 0 0 1 0 
a
b
Fig. 3 Quantification of hormone receptor status in tamoxifen-selected cell lines. a Scores for parent cell line (MCF-7), previously established 
tamoxifen-resistant cell lines (TMX2-4, TMX2-11 and TMX2-28) and the new tamoxifen-selected clones (1–21). b Relative expression of ER for parent 
cell line (MCF-7), previously established tamoxifen-resistant cell lines (TMX2-4, TMX2-11 and TMX2-28) and the new tamoxifen-selected clones 
(1–21). Analysis was conducted on ER expression levels normalized to the reference gene HPRT. Data are shown as log of the ratio of the tamoxifen-
selected cell line to MCF-7. Error bars indicate the standard deviation; N = 2 biological replicates run in technical duplicate; *p < 0.001; Results for 
TMX2-28 have been published previously [13, 23]
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Fig. 4 Relative expression of DOK7 in the 21 clonal cell lines compared to that of MCF-7 and the established TMX 2-28, TMX 2-11, and TMX 2-4. 
Analysis was conducted on DOK7 expression levels normalized to the reference gene HPRT. Data are shown as log of the ratio of the tamoxifen-
selected cell line to MCF-7. Error bars indicate the standard deviation; N = 2 biological replicates run in technical duplicate; *p < 0.05
Fig. 5 Relative expression of ELF5 in the 21 clonal cell lines compared to that of MCF-7 and the established TMX 2-28, TMX 2-11, and TMX 2-4. 
Analysis was conducted on ELF5 expression levels normalized to the reference gene HPRT. Data are shown as log of the ratio of the tamoxifen-
selected cell line to MCF-7. Error bars indicate the standard deviation; N = 2 biological replicates run in technical duplicate; *p < 0.05
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TSS of ELF5 showed wide differences among groups 
(Fig. 8b). First, ELF5 was significantly more methylated in 
PR-positive tumors than in PR-negative tumors (β =  .58 
and .39, respectively; t =  4.97; df =  45; p  <  0.001). The 
lower methylation of ELF5 in PR-negative tumors is con-
sistent with the increased expression of ELF5 observed 
in ten of our tamoxifen-selected cell lines, all of which 
had decreased levels of PR. Second, there was a trend for 
primary tumors from women treated with anti-estrogen 
therapy to have higher mean ELF5 methylation as com-
pared to the woman’s second/recurrent tumor (β =  .55 
and .49, respectively; paired t = 1.53; df = 19; p = 0.144). 
This is the first demonstration of a decrease in ELF5 
methylation in human breast tumors occurring after 
anti-estrogen treatment, and is consistent with a report 
by Kalyuga et al. showing an increase in ELF5 expression 
in luminal cell lines that acquired resistance to tamox-
ifen [8]. Of particular interest is the difference between 
PR-positive primary tumors in women of groups 1 and 
2 (Table  1). PR-positive primary tumors from women 
who had second PR-positive tumors had significantly 
higher mean methylation than did PR-positive primary 
tumors from women whose second tumor was PR-neg-
ative (β  =  .64 and .51, respectively; t  =  3.54; df  =  14; 
p = 0.003). To further examine the relationship between 
ELF5 methylation, PR status, and tumor occurrence, 
cluster analysis was performed with GenomeStudio using 
a correlation matrix (Fig. 9). Groups from women whose 
first and recurrent tumors were both PR-positive clus-
tered together (far right). Groups from first and recur-
rent tumors of women where the recurrent tumor was 
PR-negative clustered separately. The ELF5 methylation 
of PR-positive primary tumors in women who went on to 
have a PR-negative recurrence was clearly distinct from 
the ELF5 methylation of other PR-positive tumors. This 
indicates the possibility of stratification of women for tai-
lored treatment in the early stages of disease.
Widespread resistance to endocrine therapies lim-
its their usefulness and reduces patient remission. 
Previous studies have identified tamoxifen-induced cel-
lular changes. Here we characterize novel clonal cell lines 
whose diversity could represent drug resistant cancers in 
women. All of the tamoxifen-selected lines remained ER 
positive, which is consistent with results from past exper-
iments [7, 13], yet most of the lines lost expression of PR. 
We show that many of these cell lines had significantly 
elevated DOK7 and ELF5 gene expression compared 



























Fig. 6 Promoter methylation in MCF-7 cells compared with the tamoxifen-resistant cell lines, TMX2-11 and TMX2-28. Heat maps were prepared 
from available HM450BC data [12]. Average beta values, coordinate 36 values, and location are shown for the CpGs within the TSS200 and TSS1500 
regions. Left panel: nine CpGs within the TSS of DOK7 are included on the HM450BC; the box indicates the location of the six CpGs examined with 
pyrosequencing, none of which were present on the bead chip (see Fig. 7). Right panel: eight CpGs within the TSS of ELF5 are included on the 
HM450BC; the box indicates the location of the four CpGs that were examined with pyrosequencing, three of which were also present on the bead 
chip (see Fig. 7)
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methylation of DOK7 and ELF5 in the MCF-7 control 
cell culture was extremely low, and therefore, a further 
decrease in promoter methylation of DOK7 and ELF5 
was not observed to associate with the increased expres-
sion seen in the tamoxifen-selected cell lines.
However, we found the promoter region of ELF5 to be 
highly methylated in primary PR-positive tumors and 
that methylation was vastly reduced in second tumors 
occurring after anti-estrogen treatment. This finding 
is consistent with Kalyuga et  al. [8] who found higher 
expression of ELF5 to correlate with resistance to anti-
estrogens. Importantly, we also observed significantly 
higher levels of ELF5 methylation in the subset of pri-
mary, PR-positive tumors that would go on to recur as 
PR-negative, indicating an opportunity for the develop-
ment of more personalized treatment in the early stages 
of disease. To our knowledge this is the first report of 
differential ELF5 methylation in paired primary and 
recurrent breast tumors and these results deserve to be 
replicated in a larger study.
Conclusions
The novel tamoxifen-resistant cell lines described here 
display molecular differences from the parental MCF-7 
that include decreased PR protein levels, increased ELF5 
and DOK7 gene expression and will likely be useful in 
further mechanistic studies of endocrine-resistance. 
Examination of paired primary and second tumors from 
24 women, 19 of whom received anti-estrogen treatment, 
revealed a subset of primary PR-positive tumors with dis-
tinct ELF5 promoter methylation indicating the possibil-
ity of stratification of women for tailored treatment in the 
early stages of disease.
Methods
Generation of tamoxifen‑selected cell lines
MCF-7 cells were purchased from the American Type 
Culture Collection (ATCC) and grown as previously 
described [23], with tamoxifen added at 1  μM. Briefly, 
cells were maintained at 37 °C with 5 % CO2. Cells were 
grown in Falcon T-75 flasks, given fresh media twice per 
week, and split once or twice per week when 70–90  % 
confluency was obtained. The tamoxifen-selection was 
conducted in triplicate for six months resulting in three 
populations (referred to as mass cultures), one of which, 
TMX3A, was used for generating clonal lines. Cloning by 
limiting dilution was performed to assess the diversity of 
cells within the tamoxifen-selected mass culture. Tamox-
ifen-selected TMX3A cells were seeded at one cell/well 
and allowed to grow in 96-well plates for 6–7  weeks. 
Fig. 7 Confirmation of promoter methylation observed in the 
HM450BC and analysis of methylation in the novel TMX3A tamoxifen-
selected mass culture, and a sample of tamoxifen-selected clonal cell 
lines. Pyrosequencing results of bisulfite-modified DNA are shown 
for the genes a DOK7 and b ELF5. Mean and standard deviations for 
technical replicates (N = 2) are shown for each of the CpGs inter-
rogated and for the mean of the CpGs
Table 1 Demographics and tumor information for primary 
and  second tumors stratified by  progesterone receptor 
(PR) status
DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular 
carcinoma
Group Primary tumor Second tumor
(1) PR+ to PR+ (n = 10)
 Age (±SD), range 53.8 (±16.9), 37–84 61.4 (±16.7), 40–90
 Tumor type DCIS 1; IDC 8; ILC 1 DCIS 1; IDC 7; ILC 2
 Hormonal 
therapy
Yes = 10 (6 tamoxifen, 4 type unknown)
(2) PR+ to PR− (n = 6)
 Age (±SD), range 54 (±7.8), 42–62 63.3 (±7.1), 55–74
 Tumor type DCIS 1; IDC 3; ILC 1; IDC and 
ILC 1
DCIS 2; IDC 3; ILC 1
 Hormonal 
therapy
Yes = 6 (4 tamoxifen, 2 aromatase inhibitor)
(3) PR− to PR− (n = 8)
 Age (±SD), range 60.1 (±10.6), 46–79 63.3 (±11.1), 48–80
 Tumor type DCIS 1; IDC 7 DCIS 1; IDC 7
 Hormonal  
therapy
No = 5; Yes = 3 (all tamoxifen)
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Twenty-one cell lines were selected (referred to as clonal 
cell lines), expanded and cryopreserved.
Nucleic acid extraction and gene expression
RNA isolation was performed using Tri-reagent (Molec-
ular Research Center, Inc. Cat. No. E8875). DNA was iso-
lated from frozen cells using the QIAmp DNA Mini Kit 
(Qiagen Cat. No. 51304). RNA and DNA were quanti-
fied using a NanoDrop 8000 (Thermo Scientific). cDNA 
was created from isolated RNA using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) 
with added RNasin® Ribonuclease Inhibitor (Promega, 
Ref. N2511). Quantitative RT-PCR (qRT-PCR) was per-
formed on this cDNA using FastStart Universal SYBR 
Green Master mix (Roche, Cat. No. 04 913 850 001). 
Primers used for qRT-PCR are listed in Table 2. Primers 
are designed to span an exon–exon junction, therefore 
DNaseI treatment of the RNA was not necessary.
DNA methylation analyses
500 ng of DNA was bisulfite treated using the EZ DNA 
methylation-Lightning Kit (Zymo Research Cat # 
D5030). Bisulfite-treated DNA was pyrosequenced using 
the Pyromark Q24 system (Qiagen) and manufactur-
ers protocol (Qiagen), and gene methylation levels were 
detected as cysteine to thymidine ratios at specific loci. 
Primers used for pyrosequencing are listed in Table 3. For 
DOK7, the region interrogated lies within the transcrip-
tional start site region, from chromosome 4: 3434598 
PR Status + + + - - -
























Fig. 8 Promoter methylation of DOK 7 and ELF5 in primary (1°) and 
second or recurrent (2°) breast tumors by PR status of three groups of 
women: women who had a primary PR-positive tumor and a second 
PR-positive tumor (n = 10, gray boxes); women who had a primary 
PR-positive tumor and a second PR-negative tumor (n = 6; white 
boxes); and women who had a primary PR-negative tumor and a sec-
ond PR-negative tumor (n = 8; yellow boxes) Average beta distribu-
tion analysis of 9 CpG sites in the TSS of DOK7 (top) and 8 CpGs sites 
in the TSS of ELF5 (bottom). Box is quartile 1 and 3; red line is median 
average β value, whiskers are the highest and lowest values within 
×1.5 interquartile range
Fig. 9 Cluster analysis of CpGs within the TSS1500–TSS200 in ELF5 
for primary and recurrent tumors from the three groups of women 
described in Fig. 8. The PR status of the primary tumor is followed 
by the PR status of the recurrent tumor, and the data shown are for 
the tumor group not within the primary parentheses; e.g., (PR+)
PR− indicates that the data shown are for the PR-negative second 
tumors from the group of women who had a PR-positive primary and 
PR-negative recurrence. Blue box indicates CpG sites that were inter-
rogated by pyrosequencing (see Fig. 7). Coordinate 36 values and 
functional genomic location are shown
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to 3434634 (NCBI build36 coordinates). For ELF5, the 
region interrogated lies within the transcriptional start 
site region from chromosome 11 (−1): 34491972 to 
37791933 (NCBI build 36 coordinates).
Immunohistochemistry and scoring for ER, PR and HER2
Cells were seeded onto poly-l-lysine coated-slides (Poly-
sciences #22247) at a density of 200,000 cells/mL/slide 
and fixed the following day using 100  % ice-cold meth-
anol. Slides were stained on a BenchMark Ultra plat-
form using the UltraView Universal DAB Detection Kit 
with previously optimized antibodies for ER (Ventana 
CONFIRM anti estrogen receptor SP1 Rabbit mono-
clonal primary antibody), PR (Ventana CONFIRM anti 
progesterone receptor 1E2 Rabbit monoclonal primary 
antibody) and HER2 (Ventana PATHWAY anti HER-2/
neu antibody 4B5 Rabbit monoclonal antibody). Stained 
slides were dehydrated in ethanol and xylene and cov-
erslips were added manually. Slides were examined by 
a pathologist and ER and PR were recorded as Allred 
scores [29], HER2 was scored positive if greater than 
30 % of the cells showed 3+ membrane staining; scores of 
0–2 were considered negative [22].
Human breast tumors
Collection and processing of human breast tumors was 
conducted with IRB approval from Baystate Medical 
Center and the University of Massachusetts as previously 
described [30]. Breast tumor samples purified using the 
BiOstic FFPE tissue DNA isolation kit (Mo Bio, Carls-
bad, CA) were sent to the core facility at the University 
of Southern California for HM450 BeadChip (Illumina) 
analysis and detailed results are in preparation (Williams 
in prep). Twenty-four matched pairs of primary and sec-
ond/recurrent breast tumors for which methylation data 
and hormone receptor status were known and for which 
patient treatment data, and age were available were 
selected. We use the term second and recurrent inter-
changeably throughout the manuscript. It is unknown 
whether the second tumor is a true new second tumor or 
a recurrence of the first tumor. Nineteen of the 24 women 
received anti-estrogen therapy after resection of the first 
tumor, i.e. prior to resection of the second tumor (Table 1).
Data analysis
Q RT-PCR data represent biological duplicates for each 
cell line run in technical duplicate. The data were normal-
ized to hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) as a reference gene. One-way ANOVAs with 
Bonferroni post hoc tests were run to determine signifi-
cance at p < 0.05. For presentation purposes, each value 
was normalized to the average MCF-7 value for the gene 
of interest. Data were then log transformed to provide the 
expression levels relative to MCF-7, with values greater 
than 0 indicating higher expression, and values below 0 
indicating reduced expression. The average of 4 biological 
replicates was used to determine the standard deviation. 
Error bars on Figs.  3, 4, 5 and 7 represent the standard 
deviation. Data were analyzed using GraphPad Prism 
(version 3.02, La Jolla, CA). GenomeStudio Methylation 
Module (v.1.9, Illumina, San Diego, CA) was used to ana-
lyze the β values of the methylation data obtained from 
the HM450 BeadChip. Statistical comparisons between 
groups were conducted with paired and unpaired t-tests 
provided in the Data Analysis ToolPak of Excel (Micro-
soft Office Professional plus 2013).
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Estrogen receptor alpha [13] 204 F: 5′-ATG ATC AAC TGG GCG 
AAG AG-3′
R: 5′-GAT CTC CAC CAT GCC 
CTC TA-3′
ELF5 (NM_001243080.1) 129 F: 5′-TGC CCT CAC GGT AAT 
GTT GGA-3′
R: 5′-TGA TGC TCA AAG GCA 
GGG TAG-3′
DOK7 (NM_173660.4) 110 F: 5′- GCA GTG GAG GGG 
ATG ACC-3′
R: 5′ TGA CGA CGA GGA TTG 
CTC TG-3′
Table 3 Primers used for pyrosequencing
Target Product  
size (BP)
Pyrosequencing primer  
sequences (5′–3′)
ELF5 230 F: 5′-GTT TGT AGG GTA GGG GTG AGT T-3′
R: 5′-BIOTIN-ACA AAC CCT CCC AAC ACC A-3′
SEQ: 5′-TAA GGA GTAGTG TTA TAT TG-3′
DOK7 265 F: 5′- GGG AAG TAG GAT TGT TTG AAG ATT -3′
R: 5′- BIOTIN-CCA ACC AAA CTC CTT CTC CTA-3′
SEQ: 5′-GTT TTT GTT TTT TGA AAA AG-3′
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